ライフサイエンスコーパス: medical treatment

1 plantations (AVIs) and 194 deaths (115 under medical treatment).

2 th respiratory muscle fatigue and failure of medical treatment.

3 this group of stable patients compared with medical treatment.

4 t disease; surgical and other complications; medical treatment.

5 and lower utilization of guideline-directed medical treatment.

6 significantly reduced compared with standard medical treatment.

7 enotype, inflammatory status, phenotype, and medical treatment.

8 and reduced ejection fraction under optimal medical treatment.

9 ttent claudication who have not responded to medical treatment.

10 out an effective prophylactic or therapeutic medical treatment.

11 A small minority are refractory to medical treatment.

12 ho could potentially benefit from additional medical treatment.

13 quality of life higher and to recommend full medical treatment.

14 monstrated equal efficacy of surgical versus medical treatment.

15 D symptoms, although only 28% were receiving medical treatment.

16 with laser peripheral iridotomy and topical medical treatment.

17 edical treatment, or had neither surgery nor medical treatment.

18 d reduces ischaemia to a greater extent than medical treatment.

19 4% for both surgical procedures and 15% for medical treatment.

20 iculitis patients do not recur after initial medical treatment.

21 rtery disease who remain symptomatic despite medical treatment.

22 on resolved spontaneously after conservative medical treatment.

23 bout a third of patients remain resistant to medical treatment.

24 itis was diagnosed and the patient was given medical treatment.

25 1.4%, 95% CI -1.9% to -0.9%, P < 0.001) than medical treatment.

26 ents undergoing neurosurgical procedures for medical treatment.

27 in whom testing will have a direct impact on medical treatment.

28 hoice of undergoing surgery or continuing on medical treatment.

29 Most eyes have glaucoma and are on medical treatment.

30 er in patients who do not respond to optimal medical treatment.

31 d search for the best available evidence for medical treatment.

32 ype of COL3A1 variant, age at diagnosis, and medical treatment.

33 in 462 (92%) patients and 38 (8%) continued medical treatment.

34 mparable to those among patients who receive medical treatment.

35 y selected subgroup, surgery was superior to medical treatment.

36 early revascularization and received optimal medical treatment.

37 ion strategies beyond optimal anticongestive medical treatment.

38 the propagation of misinformation concerning medical treatments.

39 ead to a continuous change of guidelines for medical treatments.

40 l processes and can guide bioremediation and medical treatments.

41 essential in evaluating the effectiveness of medical treatments.

42 estoring acceptable visual acuity using only medical treatments.

43 utics is an expanding field that can improve medical treatments.

44 implications-possibly even for gender aware medical treatments.

45 logy is desired to improve the efficiency of medical treatments.

46 ole in the assessment of the benefit-risk of medical treatments.

47 onstitute a significant element of available medical treatments.

48 t-vision devices, optical communication, and medical treatments.

49 5.3]) and more frequently had limitations of medical treatment (13.1% vs 8.5%) compared with patients

50 tio was $8289 per QALY for trabeculectomy vs medical treatment, $13 896 per QALY for tube insertion v

51 All patients received medical treatment, 20 (90.9%) underwent surgery, and 4 (

52 rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %).

53 7 of 25 patients, 28%; P = 0.007) or control medical treatment (3 of 26 patients, 12%; P<0.001).

54 r revascularisation options while on optimal medical treatment; (3) patients had ongoing angina, Cana

55 erature review, 54 (96.4%) patients received medical treatment, 51 (91.1%) underwent surgery, and 27

56 es with surgery when compared with continued medical treatment (58% vs 8% [n = 80] and 73% vs 0% [n =

57 s significantly superior to that with active medical treatment (7 of 25 patients, 28%; P = 0.007) or

58 ovascular surgical procedure was better than medical treatment (97% vs 43%, P < .001) for the primary

59 daptive servo-ventilation or guideline-based medical treatment alone (control).

60 erapy plus endovascular treatment (n=103) or medical treatment alone (n=103), at four centres in Cata

61 al treatment and TEVAR (n=72) versus optimal medical treatment alone (n=68) were analyzed retrospecti

62 f systemic inflammatory burden compared with medical treatment alone in management of women with PCOS

63 roved outcomes compared with IV rtPA or best medical treatment alone in multiple randomized clinical

64 Patients receiving ET and controls receiving medical treatment alone were matched for age, baseline i

65 urgitation from 1990 to 2009, categorized by medical treatment alone, percutaneous coronary intervent

66 Compared with medical treatment alone, significantly lower mortality w

67 e insertion are cost-effective compared with medical treatment alone.

68 either percutaneous coronary intervention or medical treatment alone.

69 moderate to mild perfusion abnormalities or medical treatment alone.

70 coronary flow reserve, other PET metrics or medical treatment alone.

71 A total of 4989 patients were included: medical treatment alone=36%, percutaneous coronary inter

72 acranial stenosis) were randomly assigned to medical treatment and 186 to stenting (64 with intracran

73 s to define goals and preferences for future medical treatment and care, to discuss these goals and p

74 and record goals and preferences for future medical treatment and care.

75 e subacute-chronic phase can be managed with medical treatment and close imaging surveillance.

76 ble and unprecedented opportunity to improve medical treatment and develop preventive strategies to p

77 However, the risk of SAH on intensive medical treatment and guideline-based management/monitor

78 monic plague continues to be a challenge for medical treatment and has been classified as a reemergin

79 ient waveguiding, such as in vivo ultrasound medical treatment and imaging.

80 he pooled early mortality rate was 6.4% with medical treatment and increased to 10.2% with TEVAR and

81 ndard medical treatment, n = 54) or standard medical treatment and molecular adsorbent recirculating

82 ither standard medical treatment or standard medical treatment and molecular adsorbent recirculating

83 Standard medical treatment and molecular adsorbent recirculating

84 ondestructive testing (NDT), high-efficiency medical treatment and multidirectional underwater focusi

85 ardiac modelling are poised to revolutionize medical treatment and prevention of arrhythmia.

86 The ultimate failure of medical treatment and procedural revascularization in si

87 dissection previously randomized to optimal medical treatment and TEVAR (n=72) versus optimal medica

88 lay an important role across a wide range of medical treatments and a wide variety exist, differing i

89 EPDS present a therapeutic challenge because medical treatments and surgical modalities have met with

90 e for the development and translation of new medical treatments and therapeutics interventions affect

91 e factors could contribute to developing new medical treatments and tools to identify those most at r

92 ment, $13 896 per QALY for tube insertion vs medical treatment, and $29 055 per QALY for tube inserti

93 the clinical, laboratory, radiologic image, medical treatment, and clinical course of admission/quar

94 and court services, mental health and other medical treatment, and criminal justice involvement.

95 We adjusted the baseline characteristics, medical treatment, and drug administration data of the t

96 rms applied to 3 thematic topics: diagnosis, medical treatment, and surgical treatment.

97 with diabetes or obesity, even with optimal medical treatment, and the increased release of ROS from

98 r depressive disorder (MDD) before and after medical treatment, and to preliminarily scrutinize the a

99 opulation, particularly infections requiring medical treatment, and with diarrhea and respiratory sym

100 heat and hot substances; adverse effects of medical treatments; animal contact; environmental heat a

101 esolving any probable interfering with other medical treatments are considered.

102 nd major societal burden for which available medical treatments are currently suboptimal.

103 on, which should be considered when standard medical treatments are insufficient for the treatment of

104 Medical treatments are the mainstay approach to reduce t

105 ifferences among the elderly and the role of medical treatments are topical issues in aging societies

106 (in childhood, as radioactive fallout, or in medical treatment as low-dose radiotherapy for benign co

107 ular disease for which there is currently no medical treatment available.

108 There is currently no completely effective medical treatment available.

109 tal fibrotic lung disorder with no effective medical treatments available.

110 occurred in 6 of 23 patients (26%) receiving medical treatment before hemodynamic control was possibl

111 surgery in this cohort when compared to best medical treatment (BMT).

112 Somatostatin analogues are first line medical treatment but the disease remains uncontrolled i

113 arious diseases such as cancer and to follow medical treatments but also offers a great potential for

114 tic treatment of patients undergoing complex medical treatments can deplete commensal bacterial strai

115 ted States, including academic and community medical treatment centers, participating in the Clinical

116 h ACS reclassified from revascularization to medical treatment compared with those with non-ACS (P=0.

117 receptor imaging), and development of novel medical treatments (eg, long-acting octreotide formulati

118 acement of traditional practices with modern medical treatments, emergence of multiple pioneer scient

119 endoscopy-first approach group who underwent medical treatment, endoscopy including lithotripsy if ne

120 prove patient self-care such as adherence to medical treatment, exercise training, symptom monitoring

121 e been treated definitively in United States Medical Treatment Facilities (MTFs), reflecting the abse

122 , the US typically deployed neurosurgeons to medical treatment facilities (MTFs), while the UK did no

123 efield casualties at the Joint Force, Role 3 Medical Treatment Facility at Camp Bastion (R3), Afghani

124 t decision-making is limited until available medical treatments fail to achieve physiologic goals.

125 y be necessary in emergency situations or if medical treatment fails to stop bleeding.

126 n within 4.5 h of onset is the only approved medical treatment for acute ischaemic stroke.

127 The future success of tailored medical treatment for cancer patients will depend on the

128 would add greatly to both home and clinical medical treatment for chronic conditions.

129 either a previous COPD hospital contact, nor medical treatment for COPD, was registered.

130 There is an unmet need for better medical treatment for EP.

131 treated patients required intensification of medical treatment for heart failure (520 versus 604; haz

132 randomly assigned to receive either optimum medical treatment for heart failure alone (control group

133 There is no effective medical treatment for heart failure with preserved eject

134 ion is the most efficient and cost-effective medical treatment for infectious diseases; however, each

135 Self-reported infertility, medical treatment for infertility, time to first pregnan

136 per DALY) are more favourable than those of medical treatment for ischaemic heart disease ($500.41-7

137 Medical treatment for patent ductus arteriosus significa

138 tal inflammation and breakdown than those on medical treatment for PCOS and systemically healthy fema

139 and systemic inflammation of women receiving medical treatment for PCOS and women newly diagnosed wit

140 rd operating procedures to address expensive medical treatment for refugees in host countries, to dec

141 esearch is required to identify an effective medical treatment for retained placenta to reduce the mo

142 clinically effective nor cost-effective as a medical treatment for retained placenta, and has increas

143 Metabolic surgery is superior to medical treatment for short-term remission of T2DM and c

144 We aimed to compare vertebral stenting with medical treatment for symptomatic vertebral stenosis.

145 Surgery is more effective than medical treatment for the long-term control of obese pat

146 esigned to compare surgery with conventional medical treatment for the treatment of type 2 diabetes i

147 There is no effective medical treatment for these problems.

148 Testosterone therapy is a cornerstone of medical treatment for transgender men who choose to unde

149 a is inadequately controlled despite optimal medical treatment for type 2 diabetes.

150 We searched all phase 3 trials of medical treatments for acute ischemic stroke and corresp

151 w certainty in the effects of multiple other medical treatments for EoE: anti-interleukin-5 therapy,

152 Specific antiviral medical treatments for infected individuals are not avai

153 rred from bacteria or viruses, could provide medical treatments for microsporidian infections.

154 s need accurate evidence regarding effective medical treatments for this infection.

155 atient choice and preferred to continue with medical treatment formed a control population.

156 Many medical treatments, from oncology to psychiatry, can low

157 on [HFpEF]), and being on guideline-directed medical treatment (GDMT) at discharge (p<0.0001 for all)

158 roke in the stenting group compared with the medical treatment group was 0.81% CI 0.45-1.44; p=0.47).

159 2 (30%) in the AVR group and 73 (70%) in the medical treatment group.

160 The use of electricity in medical treatment has always been technology-driven, rat

161 No medical treatment has been reliably shown to halt or rev

162 in patients with severe emphysema on maximal medical treatment has clinically meaningful benefits.

163 Advances in medical treatments have enabled a paradigm shift in trea

164 Despite adequate medical treatment, if slow progression is seen in the fo

165 eintensification of surgical, radiation, and medical treatment in an effort to reduce toxicity while

166 Due to failure of medical treatment in controlling the glaucoma, surgery w

167 e in EAC risk between antireflux surgery and medical treatment in GERD patients without known Barrett

168 dipose-derived MSCs into STK to standardized medical treatment in human subjects without revasculariz

169 revascularization strategies are superior to medical treatment in improving survival in patients with

170 l field approaches to target individuals for medical treatment in low-income countries.

171 d the visual field (VF)-preserving effect of medical treatment in open-angle glaucoma (OAG).

172 imetazidine added to standard evidence-based medical treatment in patients who had a recent successfu

173 ed with intra-aortic balloon pump (IABP) and medical treatment in patients with AMI-CS.

174 rization (PCI or CABG) against each other or medical treatment in patients with coronary artery disea

175 ed controlled trials comparing stenting with medical treatment in patients with symptomatic vertebral

176 show substantially greater benefits of early medical treatment in the acute phase than do longer-term

177 may allow for more precise and personalized medical treatments in CRS.

178 the comparative effectiveness of first-line medical treatments in patients with POAG or ocular hyper

179 Advantages of medical treatments include the ability to treat the enti

180 (112,485 vaccinated as of May 7, 2019), and medical treatment including four investigational therapi

181 Also, deaths due to adverse events during medical treatment increased significantly after the onse

182 we consider costs of therapy and found that medical treatment involved two more office visits, where

183 er traumatic brain injury (TBI) for which no medical treatment is available.

184 i) choosing among fixed options (e.g., which medical treatment is best), or (iii) learning to create

185 If medical treatment is selected, either beta-blockers or n

186 ica can be disabling, and evidence regarding medical treatments is limited.

187 ts 2-24% of women worldwide and evidence for medical treatments is scarce.

188 es mellitus (T2DM), which responds poorly to medical treatment, is increasing.

189 During medical treatment it is critical to maintain the circula

190 Medical treatment may be effective; however, therapeutic

191 rease in deaths due to adverse events during medical treatment might reflect the effects of deteriora

192 ir uterus and who have not had a response to medical treatment, myomectomy and uterine-artery emboliz

193 domly assigned 60 patients to receive either medical treatment (n=20) or surgery by gastric bypass (n

194 either standard medical treatment (standard medical treatment, n = 54) or standard medical treatment

195 oph proliferation may be an advantage in the medical treatment of AIP-dependent human acromegaly.

196 Evidence-based medical treatment of Crohn's disease in children is reco

197 epresent a useful therapeutic option for the medical treatment of Cushing's syndrome.

198 The usual medical treatment of dystonia is pharmacotherapy with no

199 otulinum toxin (BTX) injections are the main medical treatment of facial dystonias, but injections ar

200 e pattern of results suggests that effective medical treatment of IBD in children and adolescents is

201 er integration of psychosocial care into the medical treatment of inflammatory bowel disease.

202 Medical treatment of initially uncomplicated acute Stanf

203 e, treatment of insulin resistance, and best medical treatment of intracranial stenosis.

204 Medical treatment of levodopa-induced dyskinesia (LID) i

205 We aim to provide guidance for medical treatment of luminal Crohn's disease in children

206 To summarize recent data on the medical treatment of men with incontinence due to overac

207 systematic review of studies focusing on the medical treatment of patients with aortic stenosis.

208 s of illicit drug can expedite diagnosis and medical treatment of persons who use drugs and facilitat

209 clinically effective and cost-effective for medical treatment of retained placenta following vaginal

210 rates may be explained by variations in the medical treatment of stable coronary artery disease.

211 r, the risk of recurrent stroke on intensive medical treatment of symptomatic intracranial stenosis i

212 lusion of cancer enabled the continuation of medical treatment of the underlying disease.

213 A. baumannii, which would be useful for the medical treatment of these strains.

214 gical approaches, pathologic assessment, and medical treatments of rectal cancer were considered.

215 (laparoscopic Nissen fundoplication), active medical treatment (omeprazole plus baclofen, with desipr

216 ine added depending on symptoms), or control medical treatment (omeprazole plus placebo).

217 ous Coronary Intervention [PCI] Plus Optimal Medical Treatment [OMT] Verses OMT; NCT01132495).

218 fect of non-surgical periodontal therapy and medical treatment on the level of a serologic marker of

219 he comparative effectiveness of surgical and medical treatments on fracture risk in primary hyperpara

220 FR remained stable after MSC but fell in the medical treatment only group (-3% versus -24%, P=0.04).

221 ch) plus standardized medical treatment; the medical treatment only group (n=14) included subjects ma

222 No changes in RBF occurred in medical treatment only subjects.

223 Current surgical and medical treatment options for functional mitral regurgit

224 Although medical treatment options for NEC are largely unchanged,

225 Medical treatment options for pediatric obesity remain l

226 Current surgical and medical treatment options for severe tricuspid regurgita

227 consensus includes 25 statements focused on medical treatment options.

228 Either medical treatment or catheter ablation are considered fi

229 We excluded patients who needed emergency medical treatment or inpatient admission, who were unabl

230 ons from the undiagnosed autoimmune disease, medical treatment or lifestyle associated with schizophr

231 Physician recommendations for further medical treatment or palliative treatment only at the en

232 whether they would recommend continuing full medical treatment or palliative treatment only.

233 nt of personalized stimulation protocols for medical treatment or performance enhancement.

234 r failure patients receiving either standard medical treatment or standard medical treatment and mole

235 d randomisation procedure, to receive either medical treatment or surgery by Roux-en-Y gastric bypass

236 ts, for example, those who are refractory to medical treatment or those who develop colitis-associate

237 confirmation, prior data on the efficacy of medical treatment or use of transplantation are likely l

238 Women who do not respond to medical treatment or who do not wish to retain their fer

239 risks, which can lead to recommendations of medical treatments or behavioral modifications to reduce

240 lent and nonviolent criminal convictions and medical treatments or deaths owing to assaults and unint

241 art Association functional classes I/II with medical treatment (or cardiac resynchronization therapy)

242 T-cell deficiency related to disease, medical treatment, or aging represents a major clinical

243 r undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical tr

244 y ICU status, and presence of limitations of medical treatment (p < 0.0001 all comparisons).

245 nts, including encephalopathy (18% vs 8% for medical treatment; P = .05).

246 ng system group (9.5% vs 50.0% with standard medical treatment; p = 0.004), especially in patients wi

247 ion of the infiltrate with scar formation on medical treatment, partial success as resolution followi

248 R 1A; TAVR, n = 321; SAVR, n = 313), TAVR vs medical treatment (PARTNER 1B; TAVR, n = 165), and conti

249 with PCOS (PCOS-N), 45 patients with PCOS on medical treatment (PCOS-MT), and 40 systemically healthy

250 blood pressure before its onset and optimize medical treatment plans of pre-hypertension and hyperten

251 Among a broad spectrum of medical treatments, protein therapeutics holds tremendou

252 the entire ocular surface in addition to the medical treatment provided in Group 1.

253 Physicians who recommended continuing full medical treatment rated quality of life three times high

254 nd artificial intelligence (AI) systems make medical treatment recommendations, including personalize

255 rals of patients with seizures refractory to medical treatment remain infrequent.

256 SRP together with medical treatment results in a greater reduction of syst

257 ave not been any large-scale advances in the medical treatment, some isolated successes have been rep

258 were identified and received either standard medical treatment (standard medical treatment, n = 54) o

259 address this gap, we review medical and non-medical treatment strategies for freezing of gait and pr

260 he application of atmospheric plasma jets as medical treatment strategies, there has been comparative

261 Our findings confirm that medical treatment substantially reduces the risk of earl

262 mized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG lesion.

263 ienced considerable morbidity while awaiting medical treatment that was not available in flight.

264 our decades the HIV pandemic and advances in medical treatments that also cause immunosuppression hav

265 eal transplantation and highlight developing medical treatments that may be available in the future.

266 l kinds of repair services, the provision of medical treatments, the sale of software programs, and t

267 10(5) cells/kg; n=7 each) plus standardized medical treatment; the medical treatment only group (n=1

268 Compared with medical treatment, there was a significant mortality red

269 o the ageing global population and advancing medical treatments, there are now many more people livin

270 Some choose to undergo medical treatment to align their physical appearance wit

271 k factors that could be potential targets of medical treatment to improve population health.

272 as the tailoring of preventive measures and medical treatments to the characteristics of each patien

273 The utility gained after medical treatment, trabeculectomy, and tube insertion wa

274 The mean costs for medical treatment, trabeculectomy, and tube insertion we

275 the incremental cost-effectiveness ratio of medical treatment, trabeculectomy, and tube insertion.

276 Medical treatments typically occur in the context of a s

277 , long-haul flights delay urgent, specialist medical treatment until the destination is reached or th

278 ifference of $1700 (95% CI, $1644-$1770) for medical treatment vs trabeculectomy, $3904 (95% CI, $385

279 beculectomy, $3904 (95% CI, $3858-$3953) for medical treatment vs tube insertion, and $2203 (95% CI,

280 Moreover, FFR-based deferral to medical treatment was as safe in patients with ACS as in

281 Medical treatment was commenced and he underwent a succe

282 the topical steroids during the first week, medical treatment was identical in both groups.

283 and upper body hypertension unresponsive to medical treatment was present in all patients.

284 PAD severity and medical treatment were comparable between sexes, whereas

285 OT-22 outcomes for surgical versus continued medical treatment were compared across clusters.

286 and reduced ejection fraction under optimal medical treatment were randomized to intravenous infusio

287 rt failure symptoms and severe TR on optimal medical treatment were treated with the MitraClip system

288 only available on risk factors for NAFLD and medical treatment where the group could make recommendat

289 the dose and adverse side effects of diverse medical treatments which require multiple pulse applicat

290 association strengthens the role for diet in medical treatment, which should be tested in an interven

291 In light-mediated medical treatments, which are based on PS-induced harm t

292 stic understanding guides biologically based medical treatments, which in our instance was life-savin

293 tory of illness, or in those unresponsive to medical treatments, while are only anecdotally reported

294 of central events to receive guideline-based medical treatment with adaptive servo-ventilation or gui

295 ally stimulate lung growth by combining this medical treatment with fetal TO.

296 relationship between extent of resection and medical treatment with radioactive iodine remains unknow

297 Medical treatments with systemic steroids and antimetabo

298 002) independently predicted mortality under medical treatment, with additive model predictive value

299 haemorrhage (SAH) by follow-up on intensive medical treatment, with guideline-based monitoring/manag

300 All patients received intensive medical treatment without stenting, and those with intra